These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22771598)

  • 21. Whole-Transcriptome and -Genome Analysis of Extensively Drug-Resistant Mycobacterium tuberculosis Clinical Isolates Identifies Downregulation of
    de Welzen L; Eldholm V; Maharaj K; Manson AL; Earl AM; Pym AS
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro chemotherapeutic combinations against isoniazid-resistant Mycobacterium tuberculosis and Mycobacterium fortuitum.
    Goldstein E; Eagle MC; LaCasse ML
    Appl Microbiol; 1971 Sep; 22(3):329-33. PubMed ID: 4330314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [GenoType MTBDR plus 1.0® for the detection of cross-resistance between isoniazide and ethionamide in isolates of multidrug-resistant Mycobacterium tuberculosis].
    Rueda J; Realpe T; Mejía G; Zapata E; Robledo J
    Biomedica; 2015; 35(4):541-8. PubMed ID: 26844443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of MODS assay for rapid detection of Mycobacterium tuberculosis resistance to second-line drugs in a tertiary care tuberculosis hospital in China.
    Huang Z; Li G; Chen J; Li W; Xu X; Luo Q; Xiong G; Sun J; Li J
    Tuberculosis (Edinb); 2014 Sep; 94(5):506-10. PubMed ID: 25082461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicentre laboratory validation of the nitrate reductase assay using liquid medium for the rapid detection of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis.
    Huang Z; Du J; Deng Z; Luo Q; Xiong G; Wang Y; Zhang X; Li J
    Tuberculosis (Edinb); 2018 Dec; 113():242-248. PubMed ID: 30514509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences.
    de Kantor IN; Barrera L
    Medicina (B Aires); 2007; 67(3):231-7. PubMed ID: 17628909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain. Spanish Study Group of M. tuberculosis resistance.
    Casal M; Ruiz P; Herreras A
    Int J Tuberc Lung Dis; 2000 Jun; 4(6):588-91. PubMed ID: 10864193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: preliminary results.
    Singla R; Gupta S; Gupta R; Arora VK
    Int J Tuberc Lung Dis; 2001 Jun; 5(6):559-63. PubMed ID: 11409584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A trial of treatment for pulmonary tuberculosis patients showing multiple resistance to anti-tuberculosis drugs. 1. A fundamental experiment of MIC of demethyl-chlortetracycline (LM) to M. tuberculosis and other mycobacteria].
    Takenaka T; Tsukamura M
    Kekkaku; 1970 Mar; 45(3):93-6. PubMed ID: 4987506
    [No Abstract]   [Full Text] [Related]  

  • 30. Analysis of fluoroquinolone resistance in clinical isolates of Mycobacterium tuberculosis from India.
    Sulochana S; Narayanan S; Paramasivan CN; Suganthi C; Narayanan PR
    J Chemother; 2007 Apr; 19(2):166-71. PubMed ID: 17434825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bacterial Genome-Wide Association Identifies Novel Factors That Contribute to Ethionamide and Prothionamide Susceptibility in Mycobacterium tuberculosis.
    Hicks ND; Carey AF; Yang J; Zhao Y; Fortune SM
    mBio; 2019 Apr; 10(2):. PubMed ID: 31015328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii.
    Bakuła Z; Modrzejewska M; Pennings L; Proboszcz M; Safianowska A; Bielecki J; van Ingen J; Jagielski T
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa.
    Maningi NE; Malinga LA; Antiabong JF; Lekalakala RM; Mbelle NM
    BMC Infect Dis; 2017 Dec; 17(1):795. PubMed ID: 29282012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea.
    Lee H; Cho SN; Bang HE; Lee JH; Bai GH; Kim SJ; Kim JD
    Int J Tuberc Lung Dis; 2000 May; 4(5):441-7. PubMed ID: 10815738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
    Choi J; Park SJ; Jee JG
    Eur J Med Chem; 2015 Dec; 106():157-66. PubMed ID: 26544630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preparation and biological evaluation of ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis.
    Vale N; Correia A; Silva S; Figueiredo P; Mäkilä E; Salonen J; Hirvonen J; Pedrosa J; Santos HA; Fraga A
    Bioorg Med Chem Lett; 2017 Feb; 27(3):403-405. PubMed ID: 28057421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid.
    Kaniga K; Cirillo DM; Hoffner S; Ismail NA; Kaur D; Lounis N; Metchock B; Pfyffer GE; Venter A
    J Clin Microbiol; 2016 Dec; 54(12):2963-2968. PubMed ID: 27654338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables.
    Kambli P; Ajbani K; Nikam C; Sadani M; Shetty A; Udwadia Z; Georghiou SB; Rodwell TC; Catanzaro A; Rodrigues C
    Int J Mycobacteriol; 2016 Mar; 5(1):1-6. PubMed ID: 26927983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolism of the antituberculosis drug ethionamide.
    Vale N; Gomes P; Santos HA
    Curr Drug Metab; 2013 Jan; 14(1):151-8. PubMed ID: 23215813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whole-genome sequence analysis and comparisons between drug-resistance mutations and minimum inhibitory concentrations of Mycobacterium tuberculosis isolates causing M/XDR-TB.
    Nonghanphithak D; Kaewprasert O; Chaiyachat P; Reechaipichitkul W; Chaiprasert A; Faksri K
    PLoS One; 2020; 15(12):e0244829. PubMed ID: 33382836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.